Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2022 - 03 - 09    tags : Designation    save search

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia 
Published: 2022-03-09 (Crawled : 23:00) - globenewswire.com
NTLA | $22.92 -5.56% -5.98% 860 twitter stocktwits trandingview |
Health Technology
| | O: -2.09% H: 2.75% C: 2.01%

ntla-5001 treatment fda myeloid leukemia drug leukemia 500 therapeutics drug designation intel orphan drug designation acute myeloid leukemia
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
Published: 2022-03-09 (Crawled : 22:00) - biospace.com/
CCCC | $6.86 -7.42% -8.02% 2.4K twitter stocktwits trandingview |
Health Technology
| | O: 5.67% H: 11.76% C: 9.1%

cft8634 treatment fda drug therapeutics drug designation orphan drug designation soft tissue
Rambus Accelerates Automotive SoC Design with ASIL-B Certified Embedded Hardware Security Module
Published: 2022-03-09 (Crawled : 22:00) - rambus.com
RMBS S | $59.0 -1.9% -1.98% 120 twitter stocktwits trandingview |
Electronic Technology
| | O: -1.43% H: 0.63% C: -0.18%

automotive cel security designation
Luxury Portfolio International® Puts a Spotlight on the Destinations, Dwellings and Designs that Inspire in Newest Edition of Bi-Annual Magazine
Published: 2022-03-09 (Crawled : 18:00) - prnewswire.com
CRCW | $0.0017 27.78% 0 twitter stocktwits trandingview |
Information
| | O: 0.54% H: 12.43% C: -5.95%

international tiona designation
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
Published: 2022-03-09 (Crawled : 12:00) - globenewswire.com
DSGN | $3.79 2.71% 3.4% 330 twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: 2.53% H: 12.75% C: 8.46%

treatment therapeutics preclinical therapy pre-clinical designation
Stantec intends to acquire Barton Willmore, deepening planning and design expertise in the United Kingdom
Published: 2022-03-09 (Crawled : 12:00) - globenewswire.com
STN | $79.64 -0.72% 0.0% 68K twitter stocktwits trandingview |
Industrial Services
| | O: 1.23% H: 3.29% C: 2.77%

designation
Gainers vs Losers
44% 56%

Top 10 Gainers
KAVL | $6.3 135.96% 51.63% 190K twitter stocktwits trandingview |
Wholesale Trade

PALI | $4.16 0.97% 49.07% 2.7M twitter stocktwits trandingview |
Manufacturing

JAGX | $0.1188 31.56% 35.59% 12M twitter stocktwits trandingview |
Health Technology

HUBC | $1.95 50.0% 33.67% 4.7M twitter stocktwits trandingview |
n/a

PRSO | $1.27 -1.55% 27.53% 7.4M twitter stocktwits trandingview |
Manufacturing

BRTX | $1.32 -1.49% 20.71% 3.3M twitter stocktwits trandingview |
Professional, Scientific, and T...

ONVO | $1.35 33.65% 19.83% 260K twitter stocktwits trandingview |
Health Technology

ITCI | $64.76 -1.7% 15.38% 690K twitter stocktwits trandingview |
Health Technology

MLSS | $0.5744 -5.64% 14.9% 0 twitter stocktwits trandingview |
Health Technology

VIAO | $0.308 -26.67% 12.01% 390K twitter stocktwits trandingview |
Electronic Technology


Your saved searches
Save your searches and get alerts when important news are released.